• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在症状轻微的个体中持续存在有复制能力的 SARS-CoV-2:两例病例报告。

Prolonged presence of replication-competent SARS-CoV-2 in mildly symptomatic individuals: A report of two cases.

机构信息

Laboratorio de Investigacao Medica em Virologia (LIM52), Instituto de Medicina Tropical de Sao Paulo, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil.

Departamento de Molestias Infecciosas e Parasitarias da Faculdade de Medicina, Universidade de São Paulo, São Paulo, São Paulo, Brazil.

出版信息

J Med Virol. 2021 Sep;93(9):5603-5607. doi: 10.1002/jmv.27021. Epub 2021 Apr 23.

DOI:10.1002/jmv.27021
PMID:33851749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8250959/
Abstract

It has been estimated that individuals with COVID-19 can shed replication-competent virus up to a maximum of 20 days after initiation of symptoms. The majority of studies that addressed this situation involved hospitalized individuals and those with severe disease. Studies to address the possible presence of SARS-CoV-2 during the different phases of COVID-19 disease in mildly infected individuals, and utilization of viral culture techniques to identify replication-competent viruses, have been limited. This report describes two patients with mild forms of the disease who shed replication-competent virus for 24 and 37 days, respectively, after symptom onset.

摘要

据估计,COVID-19 患者在症状出现后最多可排出复制能力的病毒长达 20 天。大多数涉及这种情况的研究都涉及住院患者和重症患者。针对轻度感染个体在 COVID-19 疾病的不同阶段可能存在 SARS-CoV-2 以及利用病毒培养技术鉴定复制能力病毒的研究受到限制。本报告描述了两例轻度疾病患者,他们分别在症状出现后 24 天和 37 天排出复制能力的病毒。

相似文献

1
Prolonged presence of replication-competent SARS-CoV-2 in mildly symptomatic individuals: A report of two cases.在症状轻微的个体中持续存在有复制能力的 SARS-CoV-2:两例病例报告。
J Med Virol. 2021 Sep;93(9):5603-5607. doi: 10.1002/jmv.27021. Epub 2021 Apr 23.
2
Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19.严重 COVID-19 患者呼吸道样本中 SARS-CoV-2 的长时间细胞培养复制。
Clin Microbiol Infect. 2021 Jun;27(6):886-891. doi: 10.1016/j.cmi.2021.02.014. Epub 2021 Feb 22.
3
Prolonged SARS-CoV-2 Positivity in Immunocompetent Patients: Virus Isolation, Genomic Integrity, and Transmission Risk.免疫功能正常患者中 SARS-CoV-2 持续阳性:病毒分离、基因组完整性和传播风险。
Microbiol Spectr. 2021 Dec 22;9(3):e0085521. doi: 10.1128/Spectrum.00855-21. Epub 2021 Nov 17.
4
Persistent SARS-CoV-2 RNA Shedding Without Evidence of Infectiousness: A Cohort Study of Individuals With COVID-19.持续的 SARS-CoV-2 RNA 脱落而无传染性证据:一项 COVID-19 患者的队列研究。
J Infect Dis. 2021 Oct 28;224(8):1362-1371. doi: 10.1093/infdis/jiab107.
5
Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant.先前感染谱系 A 的 SARS-CoV-2 变异株可保护仓鼠免受疾病侵害,但不能预防 B.1.351 SARS-CoV-2 变异株的再感染。
Emerg Microbes Infect. 2021 Dec;10(1):1284-1292. doi: 10.1080/22221751.2021.1943539.
6
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection.新型冠状病毒奥密克戎(BA.1)感染中可培养病毒的脱落持续时间。
N Engl J Med. 2022 Jul 21;387(3):275-277. doi: 10.1056/NEJMc2202092. Epub 2022 Jun 29.
7
Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents.有症状的新生儿、儿童和青少年鼻咽中的 SARS-CoV-2 具有文化适应性。
Emerg Infect Dis. 2020 Oct;26(10):2494-2497. doi: 10.3201/eid2610.202403. Epub 2020 Jun 30.
8
Detection of SARS-CoV-2 in conjunctival secretions from patients without ocular symptoms.从无眼部症状患者的结膜分泌物中检测到 SARS-CoV-2。
Infection. 2021 Apr;49(2):257-265. doi: 10.1007/s15010-020-01524-2. Epub 2020 Sep 17.
9
Experimental Models for SARS-CoV-2 Infection.SARS-CoV-2 感染的实验模型。
Mol Cells. 2021 Jun 30;44(6):377-383. doi: 10.14348/molcells.2021.0094.
10
Development of a Purified Viral Preparation for Studies of COVID-19 (SARS-CoV-2) Biology.用于 COVID-19(SARS-CoV-2)生物学研究的纯化病毒制剂的开发。
Bull Exp Biol Med. 2021 Nov;172(1):49-52. doi: 10.1007/s10517-021-05329-7. Epub 2021 Nov 17.

引用本文的文献

1
Association between development of severe COVID-19 and a polymorphism in the CIAS1 gene that codes for an inflammasome component.编码炎症小体成分的 CIAS1 基因多态性与严重 COVID-19 发病的关联。
Sci Rep. 2023 Jul 12;13(1):11252. doi: 10.1038/s41598-023-38095-9.
2
Melatonin: Regulation of Viral Phase Separation and Epitranscriptomics in Post-Acute Sequelae of COVID-19.褪黑素:调节 COVID-19 后急性后遗症中的病毒相分离和表观转录组学。
Int J Mol Sci. 2022 Jul 23;23(15):8122. doi: 10.3390/ijms23158122.
3
Inactivation of Replication-Competent Vesicular Stomatitis Virus as SARS-CoV-2 Surrogate on Common Surfaces by Disinfectants.消毒剂对常见表面上作为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)替代物的具有复制能力的水疱性口炎病毒的灭活作用。
Int J Environ Res Public Health. 2021 Jul 20;18(14):7714. doi: 10.3390/ijerph18147714.

本文引用的文献

1
Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report.严重急性呼吸综合征冠状病毒2型再感染与体液免疫衰退:一例报告
Vaccines (Basel). 2022 Dec 20;11(1):5. doi: 10.3390/vaccines11010005.
2
Transmissibility and viral replication of SARS-COV-2 in immunocompromised patients.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)在免疫功能低下患者中的传播性和病毒复制
J Med Virol. 2021 Jul;93(7):4156-4160. doi: 10.1002/jmv.26970. Epub 2021 Apr 3.
3
Clinical features and natural history of the first 2073 suspected COVID-19 cases in the Corona São Caetano primary care programme: a prospective cohort study.《Corona São Caetano 初级保健项目中 2073 例疑似 COVID-19 病例的临床特征和自然史:一项前瞻性队列研究》
BMJ Open. 2021 Jan 12;11(1):e042745. doi: 10.1136/bmjopen-2020-042745.
4
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19).COVID-19 住院患者中感染性病毒排出的持续时间和关键决定因素。
Nat Commun. 2021 Jan 11;12(1):267. doi: 10.1038/s41467-020-20568-4.
5
Clinical characteristics, cause analysis and infectivity of COVID-19 nucleic acid repositive patients: A literature review.COVID-19 核酸复阳患者的临床特征、原因分析及传染性:文献综述。
J Med Virol. 2021 Mar;93(3):1288-1295. doi: 10.1002/jmv.26491. Epub 2020 Nov 1.
6
Viable SARS-CoV-2 in various specimens from COVID-19 patients.不同 COVID-19 患者样本中存活的 SARS-CoV-2。
Clin Microbiol Infect. 2020 Nov;26(11):1520-1524. doi: 10.1016/j.cmi.2020.07.020. Epub 2020 Jul 23.
7
Obesity and mortality of COVID-19. Meta-analysis.肥胖与 COVID-19 死亡率。荟萃分析。
Obes Res Clin Pract. 2020 Jul-Aug;14(4):295-300. doi: 10.1016/j.orcp.2020.07.002. Epub 2020 Jul 9.
8
Positive SARS-CoV-2 RNA recurs repeatedly in a case recovered from COVID-19: dynamic results from 108 days of follow-up.从 COVID-19 中康复的病例中反复多次出现阳性 SARS-CoV-2 RNA:108 天随访的动态结果。
Pathog Dis. 2020 Jun 1;78(4). doi: 10.1093/femspd/ftaa031.
9
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review.严重急性呼吸综合征冠状病毒 2(SARS-CoV-2):综述。
Mol Cancer. 2020 Jun 2;19(1):100. doi: 10.1186/s12943-020-01218-1.
10
Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples.从诊断样本中预测传染性严重急性呼吸综合征冠状病毒 2。
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666. doi: 10.1093/cid/ciaa638.